PowerPoint Presentation - ASGCT...Leukapheresis Apheresis material obtained from patient via...

11

Transcript of PowerPoint Presentation - ASGCT...Leukapheresis Apheresis material obtained from patient via...

Page 1: PowerPoint Presentation - ASGCT...Leukapheresis Apheresis material obtained from patient via standard leukapheresis collection Celgene PBMC Isolation PBMCs isolated Cell Activation,
Page 2: PowerPoint Presentation - ASGCT...Leukapheresis Apheresis material obtained from patient via standard leukapheresis collection Celgene PBMC Isolation PBMCs isolated Cell Activation,
Page 3: PowerPoint Presentation - ASGCT...Leukapheresis Apheresis material obtained from patient via standard leukapheresis collection Celgene PBMC Isolation PBMCs isolated Cell Activation,
Page 4: PowerPoint Presentation - ASGCT...Leukapheresis Apheresis material obtained from patient via standard leukapheresis collection Celgene PBMC Isolation PBMCs isolated Cell Activation,
Page 5: PowerPoint Presentation - ASGCT...Leukapheresis Apheresis material obtained from patient via standard leukapheresis collection Celgene PBMC Isolation PBMCs isolated Cell Activation,
Page 6: PowerPoint Presentation - ASGCT...Leukapheresis Apheresis material obtained from patient via standard leukapheresis collection Celgene PBMC Isolation PBMCs isolated Cell Activation,
Page 7: PowerPoint Presentation - ASGCT...Leukapheresis Apheresis material obtained from patient via standard leukapheresis collection Celgene PBMC Isolation PBMCs isolated Cell Activation,
Page 8: PowerPoint Presentation - ASGCT...Leukapheresis Apheresis material obtained from patient via standard leukapheresis collection Celgene PBMC Isolation PBMCs isolated Cell Activation,
Page 9: PowerPoint Presentation - ASGCT...Leukapheresis Apheresis material obtained from patient via standard leukapheresis collection Celgene PBMC Isolation PBMCs isolated Cell Activation,
Page 10: PowerPoint Presentation - ASGCT...Leukapheresis Apheresis material obtained from patient via standard leukapheresis collection Celgene PBMC Isolation PBMCs isolated Cell Activation,
Page 11: PowerPoint Presentation - ASGCT...Leukapheresis Apheresis material obtained from patient via standard leukapheresis collection Celgene PBMC Isolation PBMCs isolated Cell Activation,

Dendritic cells in cancer immunotherapy · 2019. 10. 25. · Dendritic Cell Based Vaccines in Cancer Treatment . Vaccination . Antigen-Pulsed DC (systemic) Leukapheresis DC Generation

Dendritic cells in cancer immunotherapy · 2019. 10. 25. · Dendritic Cell Based Vaccines in Cancer Treatment . Vaccination . Antigen-Pulsed DC (systemic) Leukapheresis DC Generation

SOP.1. Diagnostic LeukApheresis€¦ · The leukapheresis staff will then begin the DLA procedure under constant nursing supervision according to the instruction provided in 4. of

SOP.1. Diagnostic LeukApheresis€¦ · The leukapheresis staff will then begin the DLA procedure under constant nursing supervision according to the instruction provided in 4. of

E4BP4-mediated inhibition of T follicular helper cell ... › articles › view › 129018 › version › 3 › pdf › render.pdfcells in peripheral blood mononuclear cells (PBMCs)

E4BP4-mediated inhibition of T follicular helper cell ... › articles › view › 129018 › version › 3 › pdf › render.pdfcells in peripheral blood mononuclear cells (PBMCs)

Characterizing Cardiovascular Outcomes Associated with … · 2020. 7. 22. · 1)Leukapheresis: T cells are extracted from the patient’s blood. 2)Cells are transduced to express

Characterizing Cardiovascular Outcomes Associated with … · 2020. 7. 22. · 1)Leukapheresis: T cells are extracted from the patient’s blood. 2)Cells are transduced to express

Towards AAV5-mediated Gene Therapy for Hemophilia A with a ... ASGCT - Hemophilia A Presentation.pdf · This presentation contains forward-looking statements. All statements other

Towards AAV5-mediated Gene Therapy for Hemophilia A with a ... ASGCT - Hemophilia A Presentation.pdf · This presentation contains forward-looking statements. All statements other

Gene Editing Workshop - ASGCT...discovery, small molecule drug repositioning, and protein engineering . Previously, as vice president of discovery at Eleven Biotherapeutics, Tom led

Gene Editing Workshop - ASGCT...discovery, small molecule drug repositioning, and protein engineering . Previously, as vice president of discovery at Eleven Biotherapeutics, Tom led

SCOTT Q. HARPER, Ph.D. CURRICULUM VITAE CURRENT … › ASGCT › media › about › Scott-Q... · SCOTT Q. HARPER, Ph.D. CURRICULUM VITAE RESEARCH SUPPORT NIH NINDS R21/R33 (1 R21

SCOTT Q. HARPER, Ph.D. CURRICULUM VITAE CURRENT … › ASGCT › media › about › Scott-Q... · SCOTT Q. HARPER, Ph.D. CURRICULUM VITAE RESEARCH SUPPORT NIH NINDS R21/R33 (1 R21

PBMC Isolation from Leukapheresis La… · 61-PBMCIsolationFromLeukapheresis-LTC-SOP-v1.0-2013-06-11 Page 1 of 35 PBMC Isolation from Leukapheresis ... Users of the ACTG/IMPAACT Lab

PBMC Isolation from Leukapheresis La… · 61-PBMCIsolationFromLeukapheresis-LTC-SOP-v1.0-2013-06-11 Page 1 of 35 PBMC Isolation from Leukapheresis ... Users of the ACTG/IMPAACT Lab

Reference ID: 3698474 · blood for collection by leukapheresis (1.4) •Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ ... short intravenous infusion

Reference ID: 3698474 · blood for collection by leukapheresis (1.4) •Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ ... short intravenous infusion

BR27059-Human Primary Cells - Stemcell Technologies · 2021. 7. 2. · Peripheral Blood Mononuclear Cells Diseased State PBMCs Access cryopreserved PBMCs isolated from donors with:

BR27059-Human Primary Cells - Stemcell Technologies · 2021. 7. 2. · Peripheral Blood Mononuclear Cells Diseased State PBMCs Access cryopreserved PBMCs isolated from donors with:

8°Congreso Argentino de Infectología Pediátrica. Abril ...a/Lunes 24/Dra... · 14.3 años HIV DNA (copies/million PBMCs)

8°Congreso Argentino de Infectología Pediátrica. Abril ...a/Lunes 24/Dra... · 14.3 años HIV DNA (copies/million PBMCs)

Report on a Collaborative study for Proposed 2 nd ... · haematopoietic progenitor cells into the peripheral blood for collection by leukapheresis and haematopoietic stem-cell transplantation.

Report on a Collaborative study for Proposed 2 nd ... · haematopoietic progenitor cells into the peripheral blood for collection by leukapheresis and haematopoietic stem-cell transplantation.

Curing HIV: Coping with Hope - PAETCpaetc.org/wp-content/uploads/2014/06/Coping2014.Mitsuyasu.ARS_.… · Autologous ZFN CCR5-Disrupted CD4+ T-cells Leukapheresis Enriched CD4+ Adenoviral

Curing HIV: Coping with Hope - PAETCpaetc.org/wp-content/uploads/2014/06/Coping2014.Mitsuyasu.ARS_.… · Autologous ZFN CCR5-Disrupted CD4+ T-cells Leukapheresis Enriched CD4+ Adenoviral

Characterization of a novel salivary immunosuppressive ... · Means of ConA-unstimulated wells were previously subtracted (net 10³ c.p.m.). Naive human PBMCs : ... Antwerp, Belgium)

Characterization of a novel salivary immunosuppressive ... · Means of ConA-unstimulated wells were previously subtracted (net 10³ c.p.m.). Naive human PBMCs : ... Antwerp, Belgium)

Final leukapheresis

Final leukapheresis

LabResource:StemCellLine ... et al 2016.pdf · UNCORRECTED PROOF ARTICLEINFO Article history: Received11October2016 Accepted1November2016 Availableonlinexxx ABSTRACT PeripheralBloodMononuclearCells(PBMCs

LabResource:StemCellLine ... et al 2016.pdf · UNCORRECTED PROOF ARTICLEINFO Article history: Received11October2016 Accepted1November2016 Availableonlinexxx ABSTRACT PeripheralBloodMononuclearCells(PBMCs

Leukapheresis* by Continuous Flow Centrifugation (CFC) in - Blood

Leukapheresis* by Continuous Flow Centrifugation (CFC) in - Blood

125554Orig1s000 - Food and Drug Administration by downregulating the immune response. Blocking this signaling pathway thus ... Ex vivo studies using human PBMCs ... signature . ...

125554Orig1s000 - Food and Drug Administration by downregulating the immune response. Blocking this signaling pathway thus ... Ex vivo studies using human PBMCs ... signature . ...

Phase-Appropriate Viral Clearance Strategy for Sf9 ......ASGCT -2020Annual Meeting I May 12 –15, 2020I VirtualPhase-Appropriate Viral Clearance Strategy for Sf9/BaculovirusBased

Phase-Appropriate Viral Clearance Strategy for Sf9 ......ASGCT -2020Annual Meeting I May 12 –15, 2020I VirtualPhase-Appropriate Viral Clearance Strategy for Sf9/BaculovirusBased

RODRIGO BARBANO WEINGRILL EXPRESSÃO DA … · significativa do potencial migratório das PBMCs (7 ± 1,63) comparado ao controle (ODN scramble, 13 ± 2,16). Resultados similares

RODRIGO BARBANO WEINGRILL EXPRESSÃO DA … · significativa do potencial migratório das PBMCs (7 ± 1,63) comparado ao controle (ODN scramble, 13 ± 2,16). Resultados similares